Nasdaq
$6.84▼ 1.23%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $359.5MShares out 52.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 10.2After-hours26.10.03 05:154Ownership#●●●
Avalo Therapeutics, Inc.
Insider Rita Jain of Avalo Therapeutics reported a change in beneficial ownership of securities as of September 30, 2026. This filing serves as a Form 4 notification regarding the insider's equity holdings.…more
$6.84-1.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:154Ownership
Avalo Therapeutics, Inc.
Avalo Therapeutics insider Kevin Robert Lind reported a change in beneficial ownership of securities as of September 30, 2026. This filing serves as a Form 4 statement regarding the executive's stock holdings.…more
$6.84-1.23%vs prev closeView filingShare - 10.2After-hours26.10.03 05:154Ownership
Avalo Therapeutics, Inc.
Insider Philip Ron M of Avalo Therapeutics reported a change in beneficial ownership of company securities as of September 30, 2026. This filing serves as a Form 4 statement regarding the insider's stock holdings.…more
$6.84-1.23%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29After-hours26.09.30 05:01#●●●#●●●
Avalo Therapeutics Grants Stock Options to New Employees
Avalo Therapeutics announced the grant of stock options for 101,600 shares to three new employees as an employment inducement. This move is a standard compensation practice under Nasdaq rules and does not significantly impact the company's financial outlook.…more
$6.84-1.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.23Pre-market26.09.23 20:00
●●●●●●●● ●●●●● ●●●●●●
Avalo Therapeutics will present Phase 2 clinical trial results for its drug candidate at the upcoming EADV Congress. As this is a standard presentation of research findings, its immediate impact on the stock price is expected to be neutral.…more
$6.84-1.23%vs prev close - 9.4After-hours26.09.05 05:05
●●●●●●●● ●●●●● ●●●●●●
Avalo Therapeutics has granted stock options for 78,000 shares to six new employees in accordance with Nasdaq listing rules. This is a standard compensation practice for talent acquisition and does not materially impact the company's valuation.…more
$6.84-1.23%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report